The Claim
Oral administration of BLS-M22 in aged mdx mice with advanced Duchenne muscular dystrophy does not result in a significant increase in muscle fiber cross-sectional area or a significant reduction in fibrosis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In aged mice with a severe form of muscular dystrophy, taking BLS-M22 by mouth does not lead to larger muscle fibers or less scar tissue in the muscles.
See the scientific wording
In aged mdx mice with advanced Duchenne muscular dystrophy, oral BLS-M22 treatment does not significantly increase muscle fiber cross-sectional area or reduce fibrosis, indicating limited regenerative capacity despite immune activation.
The immune system makes antibodies that block a protein that normally stops muscle growth, but the muscle tissue is too damaged with scar tissue and has lost its ability to make new muscle fibers, so the muscle does not get bigger or heal.
What the research says
1 studyThe probiotic made the mice’s immune system react and helped them run a little better, but their muscles didn’t get bigger or heal the scar tissue — meaning the disease was too far along for this treatment to fix the damage.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.